Common data analysis pitfalls in clinical research and how to avoid them

When a new drug shows promise, the excitement in the lab is palpable. Yet the real test begins when we turn raw numbers into conclusions that will affect real patients. A single misstep in data analysis can turn a breakthrough into a setback, and that’s why today’s topic matters more than ever.

Why data analysis matters more than ever

Clinical research has become a data‑rich enterprise. Wearable sensors, electronic health records, and high‑throughput genomics dump terabytes of information into our pipelines. With so much to sift through, the temptation to cut corners or rely on “quick fixes” grows. The stakes are high: regulatory decisions, patient safety, and public trust all hinge on the integrity of our statistical work.

Pitfall #1 – Ignoring missing data

The silent thief

Missing data are like silent thieves; they slip in unnoticed and steal the validity of your results. In a recent oncology trial I consulted on, 12 % of tumor measurements were missing because a scanner malfunctioned at one site. The initial analysis simply omitted those patients, inflating the response rate.

How to avoid it

Explore the pattern – Ask yourself whether data are missing completely at random (MCAR), at random (MAR), or not at random (MNAR). Each scenario calls for a different remedy.
Impute wisely – Simple mean imputation can bias variance. Consider multiple imputation, which creates several plausible datasets and pools the results. It respects uncertainty and yields more reliable confidence intervals.
Document everything – A transparent missing‑data handling plan in the statistical analysis plan (SAP) protects you during audits and peer review.

Pitfall #2 – Over‑reliance on p‑values

The p‑value trap

For decades, a p‑value below 0.05 has been treated as a golden ticket. In a vaccine efficacy study I helped design, the primary endpoint just missed that threshold (p = 0.051). The team was tempted to claim “no effect,” ignoring the fact that the confidence interval still suggested a clinically meaningful benefit.

How to avoid it

Shift focus to effect sizes – Report the magnitude of the treatment effect and its confidence interval. This tells clinicians how much benefit to expect, not just whether it is statistically significant.
Pre‑specify thresholds – If you have a clinically relevant difference in mind, use it to interpret results rather than relying on an arbitrary p‑value cut‑off.
Consider Bayesian methods – They provide a probability that the treatment effect exceeds a meaningful threshold, which can be more intuitive for decision‑makers.

Pitfall #3 – Ignoring multiplicity

When one test leads to many

In a phase II oncology trial, we examined tumor shrinkage across five molecular sub‑groups. Each subgroup was analyzed separately, and one showed a strikingly low p‑value. The press release highlighted this “breakthrough,” but the statistical correction for multiple comparisons was missing, inflating the false‑positive risk.

How to avoid it

Plan adjustments upfront – Use methods like Bonferroni correction, Holm’s step‑down, or false discovery rate control, depending on the number and correlation of tests.
Group similar outcomes – If possible, combine related endpoints into a composite measure to reduce the number of comparisons.
Report both adjusted and unadjusted results – Transparency lets readers see the raw signal and the corrected interpretation.

Pitfall #4 – Misinterpreting subgroup analyses

The “post‑hoc” nightmare

Subgroup analyses are tempting because they promise personalized insights. Yet when they are not pre‑specified, they become exploratory fishing expeditions. In a cardiovascular trial, an unexpected benefit appeared in patients over 70 years old. The investigators later realized the sample size in that subgroup was tiny, and the result vanished in a larger dataset.

How to avoid it

Pre‑specify subgroups – Include them in the SAP with clear hypotheses.
Limit the number – Focus on biologically plausible subgroups rather than testing every demographic slice.
Validate findings – Replicate promising subgroup signals in an independent cohort before drawing conclusions.

Pitfall #5 – Over‑fitting predictive models

The “too good to be true” model

Machine‑learning models are now common in trial data exploration. I once saw a model that claimed 98 % accuracy in predicting adverse events, but it had been trained on the same data it was tested on. The model was essentially memorizing noise.

How to avoid it

Separate training and validation – Reserve a portion of the data (or use external data) for testing the model’s performance.
Use regularization – Techniques like Lasso or Ridge penalize overly complex models, keeping them generalizable.
Report performance metrics – Include sensitivity, specificity, and area under the ROC curve, not just overall accuracy.

Pitfall #6 – Neglecting data provenance

The “unknown origin” problem

When data come from multiple sites, inconsistencies in measurement units, coding conventions, or timing can creep in unnoticed. In a multi‑center diabetes trial, one site recorded glucose in mg/dL while another used mmol/L, leading to a spurious treatment effect until the discrepancy was discovered.

How to avoid it

Standardize data collection – Use common data elements and a shared data dictionary across sites.
Audit trails – Keep logs of any data transformations, cleaning steps, and version changes.
Cross‑check with source documents – Randomly verify that the analysis dataset matches the original case report forms.

A personal reminder

I still recall the first time I missed a missing‑data flag. I was fresh out of my PhD, eager to prove a hypothesis, and I simply dropped the incomplete rows. The manuscript was rejected, and the reviewer’s comment—“Did you consider the impact of missing data?”—still haunts me in a good way. It taught me that humility and rigor go hand‑in‑hand; data analysis is not a sprint, it’s a marathon where every checkpoint matters.

Putting it all together

Avoiding these pitfalls does not require a crystal ball, just a disciplined workflow:

Draft a detailed SAP before the first patient is enrolled.
Conduct a data‑quality audit after database lock.
Apply appropriate statistical methods, documenting every decision.
Seek independent review—statistical code review, data monitoring committees, or a trusted colleague.

When we treat data analysis as a collaborative, transparent process, we protect patients, uphold scientific integrity, and keep the promise of clinical research alive.